Form 4: Director Richard Klausner Receives Lyell Stock Options
Statement of Changes in Beneficial Ownership
Lyell Immunopharma director Richard Klausner was granted 9,250 stock options as part of his ongoing service to the company.
Summary
- Director Richard Klausner received a grant of 9,250 stock options on June 10, 2026.
- The options have an exercise price of $13.22 per share.
- The options are set to expire on June 9, 2036.
- The reporting person maintains direct ownership of 148,391 shares and indirect ownership of 42,166 shares through family trusts.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market signal.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified in this filing.
Risks
- The value of the granted options is subject to the future market performance of Lyell Immunopharma common stock.
Future Outlook
The options vest on the earlier of the next annual meeting of stockholders following June 10, 2026, or the first anniversary of the grant date, provided the director maintains continuous service.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with corporate performance goals.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard corporate governance practices for NASDAQ-listed life sciences companies.
Related Party Transactions
- The reporting person holds shares through The Klausner Family Revocable Trust and several Delaware Trusts for which he acts as grantor.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensatory grant to a director.
Next Steps
- Vesting of the 9,250 option shares upon the earlier of the next annual meeting or June 10, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/30/2025 | Effective date of 1-for-20 reverse stock split. |
| 06/10/2026 | Date of option grant and earliest transaction. |
| 06/09/2036 | Expiration date of the granted stock options. |
Keywords
Lyell Immunopharma, LYEL, Director Compensation, Stock Options, Insider Trading, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.